Literature DB >> 16574760

Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay.

Jin Song1, Manisha Patel, C Nicole Rosenzweig, Yee Chan-Li, Lori J Sokoll, Eric T Fung, Nam-Ho Choi-Miura, Michael Goggins, Daniel W Chan, Zhen Zhang.   

Abstract

BACKGROUND: Several proteolytically derived fragments from the proline-rich region (PRR) of human inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4) have been identified by surface-enhanced or matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS or MALDI-TOF-MS) as potential disease markers.
METHODS: Previously, we developed a SELDI-based immunoassay that can simultaneously distinguish and quantify multiple isoforms/variants of a protein/peptide of interest. In this study, we used this high-throughput approach to quantify and characterize the extensive fragmentation within the PRR of human serum ITIH4 and determined its association with different disease conditions. The ITIH4-related fragments were first immunocaptured by use of beads coupled with peptide-specific antibodies. The eluates were then studied by SELDI-TOF-MS. In addition, freshly collected and immediately processed serum and plasma samples were used to analyze the ex vivo stability of these ITIH4 fragments.
RESULTS: Human serum ITIH4 was shown to be extensively proteolytically processed within the PRR, and its fragmentation patterns were closely associated with different disease conditions. Fragmentation patterns were generally consistent with cleavages by endoprotease followed by exoprotease actions. Observed fragments changed little under different assay conditions or blood collection and processing procedures.
CONCLUSIONS: The fragmentation patterns within the PRR of human serum ITIH4 are associated with different disease conditions and may hold important diagnostic information. These fragmentation patterns could be useful as potential biomarkers for detection and classification of cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16574760     DOI: 10.1373/clinchem.2005.065722

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  36 in total

1.  Proteomic identification of serum peptides predicting subsequent spontaneous preterm birth.

Authors:  M Sean Esplin; Karen Merrell; Robert Goldenberg; Yinglei Lai; Jay D Iams; Brian Mercer; Catherine Y Spong; Menachem Miodovnik; Hygriv N Simhan; Peter van Dorsten; Mitchell Dombrowski
Journal:  Am J Obstet Gynecol       Date:  2010-11-11       Impact factor: 8.661

Review 2.  Enzymes and related proteins as cancer biomarkers: a proteomic approach.

Authors:  Shu-Ling Liang; Daniel W Chan
Journal:  Clin Chim Acta       Date:  2007-02-20       Impact factor: 3.786

3.  ITIH4 and Gpx3 are potential biomarkers for amyotrophic lateral sclerosis.

Authors:  Hirotaka Tanaka; Masamitsu Shimazawa; Masafumi Takata; Hideo Kaneko; Kazuhiro Tsuruma; Tsunehiko Ikeda; Hitoshi Warita; Masashi Aoki; Mitsunori Yamada; Hitoshi Takahashi; Isao Hozumi; Hiroshi Minatsu; Takashi Inuzuka; Hideaki Hara
Journal:  J Neurol       Date:  2013-02-23       Impact factor: 4.849

4.  Search for breast cancer biomarkers in fractionated serum samples by protein profiling with SELDI-TOF MS.

Authors:  Annemieke W J Opstal-van Winden; Jos H Beijnen; Arnoud Loof; Waander L van Heerde; Roel Vermeulen; Petra H M Peeters; Carla H van Gils
Journal:  J Clin Lab Anal       Date:  2012-01       Impact factor: 2.352

5.  Genetic Overlap Between Schizophrenia and Volumes of Hippocampus, Putamen, and Intracranial Volume Indicates Shared Molecular Genetic Mechanisms.

Authors:  Olav B Smeland; Yunpeng Wang; Oleksandr Frei; Wen Li; Derrek P Hibar; Barbara Franke; Francesco Bettella; Aree Witoelar; Srdjan Djurovic; Chi-Hua Chen; Paul M Thompson; Anders M Dale; Ole A Andreassen
Journal:  Schizophr Bull       Date:  2018-06-06       Impact factor: 9.306

Review 6.  Current status and prospects of clinical proteomics studies on detection of colorectal cancer: hopes and fears.

Authors:  M E de Noo; R A E M Tollenaar; A M Deelder; L H Bouwman
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

Review 7.  Proteomic contributions to personalized cancer care.

Authors:  John M Koomen; Eric B Haura; Gerold Bepler; Rebecca Sutphen; Elizabeth R Remily-Wood; Kaaron Benson; Mohamad Hussein; Lori A Hazlehurst; Timothy J Yeatman; Lynne T Hildreth; Thomas A Sellers; Paul B Jacobsen; David A Fenstermacher; William S Dalton
Journal:  Mol Cell Proteomics       Date:  2008-07-29       Impact factor: 5.911

8.  Patients with ovarian carcinoma excrete different altered levels of urine CD59, kininogen-1 and fragments of inter-alpha-trypsin inhibitor heavy chain H4 and albumin.

Authors:  Siti S Abdullah-Soheimi; Boon-Kiong Lim; Onn H Hashim; Adawiyah S Shuib
Journal:  Proteome Sci       Date:  2010-11-17       Impact factor: 2.480

9.  Specific Investigation of Sample Handling Effects on Protease Activities and Absolute Serum Concentrations of Various Putative Peptidome Cancer Biomarkers.

Authors:  Irene van den Broek; Rolf W Sparidans; Jan H M Schellens; Jos H Beijnen
Journal:  Clin Proteomics       Date:  2010-09-30       Impact factor: 3.988

10.  Identification of macrophage migration inhibitory factor and human neutrophil peptides 1-3 as potential biomarkers for gastric cancer.

Authors:  Y Mohri; T Mohri; W Wei; Y-J Qi; A Martin; C Miki; M Kusunoki; D G Ward; P J Johnson
Journal:  Br J Cancer       Date:  2009-06-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.